CD19 and acute myeloid leukemia: In the present study, we summarized the treatment outcome of seven children with R/R‐AML treated with anti‐CLL1‐based CAR T‐cell therapy, aiming to shed new light on the translation of anti‐CD19 CAR T‐cell therapy in B‐ALL into R/R‐AML treatment.